Abstract:BackgroundThere is no method of predicting human cytomegalovirus (HCMV) outcomes in allogeneic hematopoietic stem cell transplant recipients clinically, leading in some cases to excessive or insufficient antiviral therapy. We evaluated the early immune response of recipients with disparate HCMV outcomes.MethodsThe HCMV outcomes of recipients were determined by long-term monitoring of HCMV DNA levels posttransplant. HCMV IgG and IgM concentrations at 1 week before and 1 week after transplantation, absolute lymphocyte counts, and HCMV-specific IFN-γ secreting cells at 1 month posttransplant were evaluated based on HCMV outcome.ResultsAll recipients were negative for HCMV IgM. Significant differences between recipients with and without HCMV reactivation were observed in pre- and post-transplant HCMV IgG antibody levels, absolute lymphocyte counts, and HCMV-specific IFN-γ secreting cells (P < 0.05). HCMV IgG antibody levels significantly increased after transplantation in recipients with HCMV reactivation (P = 0.032), but not in those without reactivation. Multivariate analysis revealed that except for the absolute lymphocyte count these biomarkers were related to HCMV reactivation, independent of other clinical factors. In time-to-event analyses, lower levels of these biomarkers were associated with an increased 150-day cumulative incidence of HCMV reactivation (log-rank P < 0.05). In recipients with HCMV reactivation, the duration of HCMV DNAemia had negative correlation with HCMV-specific IFN-γ-secreting cells (P = 0.015, r = -0.372). The relationships between the peak HCMV DNA load and absolute lymphocyte count and HCMV-specific IFN-γ-secreting cells followed the same trends (P = 0.026, r = -0.181 and P = 0.010, r = -0.317).ConclusionsHCMV IgG, absolute lymphocyte count, and HCMV-specific IFN-γ secreting cells represent the humoral and cellular immune response. Early monitoring of these immune markers could enable prediction of HCMV outcomes posttransplant and assessment of the severity of HCMV DNAemia.

CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation.

Improving Cytomegalovirus-Specific T Cell Reconstitution after Haploidentical Stem Cell Transplantation.

Cytomegalovirus-specific T cell immunity reconstitution following allogeneic hematopoietic stem cell transplantation: a pilot stduy

[Cytomegalovirus Specific Cytotoxic T Lymphocytes for Treatment of Refractory Cytomegalovirus Infection in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation].

S291: LONG-TERM SAFETY AND EFFICACY OF CMV/EBV-SPECIFIC T CELLS FOR CMV AND EBV CO-REACTIVATION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION

Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients

[Cytomegalovirus-Specific T Cells Immune Reconstitution after Human Leukocyte Antigen Matched Sibling Donor Allogeneic Bone Marrow Plus Peripheral Blood Hematopoietic Stem Cell Transplantation].

Current and future strategies for the prevention and treatment of cytomegalovirus infections in transplantation

Early Immune Surveillance to Predict Cytomegalovirus Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.

Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation.

Immune Reconstitution to Cytomegalovirus Following Partially Matched-Related Donor Transplantation: Impact of in Vivo T-cell Depletion and Granulocyte Colony-Stimulating Factor-Primed Peripheral Blood/bone Marrow Mixed Grafts.

Emerging concepts of CMV in transplantation

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update

Human Cytomegalovirus Infection: A Considerable Issue Following Allogeneic Hematopoietic Stem Cell Transplantation (Review)

Adoptive Therapy with Cytomegalovirus-Specific T Cells for Cytomegalovirus Infection after Haploidentical Stem Cell Transplantation and Factors Affecting Efficacy.

CMV Infection Combined with Acute GVHD Associated with Poor CD8+ T-cell Immune Reconstitution and Poor Prognosis Post-Hla-matched Allo-Hsct

Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide

Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review

Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation

Efficacy of pp65‐specific TCR‐T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation